- Home
- BCDA vs MARPS Comparison
BCDA vs MARPS Comparison
Compare BCDA & MARPS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BCDA
- MARPS
- Stock Information
- Founded
- BCDA N/A
- MARPS 1956
- Country
- BCDA United States
- MARPS United States
- Employees
- BCDA N/A
- MARPS N/A
- Industry
- BCDA Biotechnology: Pharmaceutical Preparations
- MARPS Oil & Gas Production
- Sector
- BCDA Health Care
- MARPS Energy
- Exchange
- BCDA Nasdaq
- MARPS Nasdaq
- Market Cap
- BCDA 7.9M
- MARPS 7.9M
- IPO Year
- BCDA N/A
- MARPS N/A
- Fundamental
- Price
- BCDA $2.68
- MARPS $4.05
- Analyst Decision
- BCDA Strong Buy
- MARPS
- Analyst Count
- BCDA 1
- MARPS 0
- Target Price
- BCDA $25.00
- MARPS N/A
- AVG Volume (30 Days)
- BCDA 73.1K
- MARPS 29.2K
- Earning Date
- BCDA 11-06-2024
- MARPS 01-01-0001
- Dividend Yield
- BCDA N/A
- MARPS 8.30%
- EPS Growth
- BCDA N/A
- MARPS N/A
- EPS
- BCDA N/A
- MARPS 0.36
- Revenue
- BCDA $428,000.00
- MARPS $1,044,997.00
- Revenue This Year
- BCDA $6.92
- MARPS N/A
- Revenue Next Year
- BCDA N/A
- MARPS N/A
- P/E Ratio
- BCDA N/A
- MARPS $11.67
- Revenue Growth
- BCDA 0.71
- MARPS N/A
- 52 Week Low
- BCDA $1.96
- MARPS $3.77
- 52 Week High
- BCDA $23.25
- MARPS $6.50
- Technical
- Relative Strength Index (RSI)
- BCDA 49.01
- MARPS 47.45
- Support Level
- BCDA $2.39
- MARPS $3.98
- Resistance Level
- BCDA $2.90
- MARPS $4.19
- Average True Range (ATR)
- BCDA 0.18
- MARPS 0.23
- MACD
- BCDA -0.00
- MARPS -0.02
- Stochastic Oscillator
- BCDA 53.70
- MARPS 8.54
About BCDA BioCardia Inc.
BioCardia Inc is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with significant unmet medical needs. Its two cell therapy platforms derived from the bone marrow. CardiAMP autologous mononuclear cell therapy platform is being advanced for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia (CMI). Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being an "off the shelf" cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome (ARDS).
About MARPS Marine Petroleum Trust Units of Beneficial Interest
Marine Petroleum Trust is a U.S based royalty trust. It provides administration and liquidation of rights to payments from oil and natural gas leases in the Gulf of Mexico. The Trust's subsidiary holds title to interests in properties which are situated offshore of Louisiana. The revenues of the trust are derived from the oil and natural gas production activities of third parties.